Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-1 IM: Immune Modulators for COVID-19
NCT04593940Phase 3Completed
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of infliximab, abatacept, cenicriviroc in coronavirus disease 2019 (COVID-19). Started Oct 2020; status: completed.
02
Drugs
infliximababataceptcenicriviroc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04593940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593940.